Name | Plogosertib |
Description | Plogosertib (CYC140) is an orally active, selective, potent, and ATP-competitive PLK1 inhibitor with an IC50 value of 3 nM.Plogosertib exhibits antiproliferative and anticancer activity and can be used for the study of solid and hematologic tumors.
and hematologic tumors. |
In vitro | In KYSE-410 cells, Plogosertib (0, 0.07, 0.15, 0.3, 0.6, 1.25 μM; 72 hours) inhibits cell proliferation in a concentration-dependent manner[2]. |
In vivo | In the HL60 promyelocytic leukemia xenograft model, Plogosertib (40, 54, 67 mg/kg, qd 5/2/5; oral administration) inhibited tumor growth (>87%) without significant loss in body weight[2]. |
Storage | keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Keywords | AC010220.2HCl | AC-010220 | CYC-140 | CYC 140 | AC 010220 | AC-220 | AC010220 | AC 220 | Quizartinib dihydrochloride | Plogosertib | Quizartinib HCl | Quizartinib |
Inhibitors Related | Onvansertib | T521 | (E/Z)-Rigosertib sodium | SBE13 Hydrochloride | Pyridoxine | Rigosertib sodium | 3MB-PP1 | Poloxin-2 | BI 2536 | GSK461364 |
Related Compound Libraries | Bioactive Compound Library | Bioactive Compounds Library Max |